Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 121.37

+2.6%

Jan 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: zax	4/5/2020 11:19:25 AM
	of 961

Covid Report: Gilead Pops After EMA Recommends Its Coronavirus Drug investors.com The European Medicines Agency recommended compassionate use of Gilead Sciences' (GILD) experimental drug, remdesivir, as a coronavirus treatment on Friday — sending GILD stock up. Initial results from remdesivir in late-stage studies are due imminently. But European officials made the recommendation based on laboratory studies. These studies have shown remdesivir can act against SARS and MERS — diseases caused by other coronaviruses. Remdesivir is currently in clinical testing as a coronavirus treatment. But not all patients can qualify for testing. The EMA decision doesn't approve remdesivir, but it opens access to patients who are extremely sick with Covid-19, the disease caused by the new coronavirus, dubbed SARS-CoV-2. "The CHMP (Committee for Medicinal Products for Human Use) acknowledges the need for a harmonized approach to compassionate use in the EU to allow access to remdesivir for patients who are not eligible for inclusion in clinical trials," CHMP Chair Harald Enzmann said in a written statement. GILD Stock Rises On Coronavirus Treatment News On the stock market today, GILD stock rose 1.6% to 78.21. It's important to note that GILD stock has been volatile surrounding its efforts in coronavirus treatment. Recently, Gilead decided to suspend its compassionate-use program for remdesivir in the U.S. due to an overwhelming number of requests. Instead, the biotech company is working on an expanded access program that would allow institutions to request the coronavirus treatment on behalf of multiple people. ... investors.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next